Iradimed Corp. (NASDAQ: IRMD) reported Q2 EPS of $0.14, $0.05 better than the analyst estimate of $0.09. Revenue for the quarter came in at $9.8 million versus the consensus estimate of $8.46 million.

GUIDANCE:

Iradimed Corp. sees Q3 2021 EPS of $0.16-$0.17, versus the consensus of $0.13. Iradimed Corp. sees Q3 2021 revenue of $10.3-10.5 million, versus the consensus of $9.4 million.

Iradimed Corp. sees FY2021 EPS of $0.60-$0.62, versus the consensus of $0.53. Iradimed Corp. sees FY2021 revenue of $40-40.4 million, versus the consensus of $37.5 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.